Cell Therapeutics' Pixantrone Under NICE Consideration

Biopharmaceutical company Cell Therapeutics, Inc. has announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom (UK), has issued second draft guidance on Pixurvi (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (aggressive B-cell NHL).

An independent Appraisal Committee for NICE got together on Sept. 11, 2013 to weigh the cost effectiveness of pixantrone using Cell Therapeutics' initial patient access scheme that was approved by the Department of Health in July of 2013.

Reassessing evidence

This committee concluded that the patient access scheme failed to overcome the "uncertainties in the evidence for pixantrone's clinical effectiveness" and is requesting that consultees, including CTI, healthcare professionals and members of the public, not comment on the draft guidance via the NICE website. A final Appraisal Committee meeting is scheduled for the middle of November, and at this time CTI is expected to learn whether NICE will consider a so-called enhanced patient access scheme in the UK.

The European Commission (EC) granted conditional marketing authorization in the European Union for pixantrone in May of 2012 as a monotherapy for adult patients with multiply relapsed or refractory aggressive B-cell NHL. Approval was based on the results of the EXTEND (PIX301) pivotal randomized Phase III clinical trial. The drug has therefore been available to patients in eight European countries for more than a year.

Source: CTI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap